Protagenic Therapeutics, Inc.\new annual working capital
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Working Capital Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's working capital was $511,107 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $511,107 | $5.5M | — |
| 2025 | 2025-03-31 | −$5.0M | — | — |
| 2024 | 2024-12-31 | $940,108 | −$2.6M | −73.48% |
| 2023 | 2023-12-31 | $3.5M | −$3.4M | −48.74% |
| 2022 | 2022-12-31 | $6.9M | −$3.3M | −32.60% |
| 2021 | 2021-12-31 | $10.3M | $10.0M | +4479.30% |
| 2020 | 2020-12-31 | $224,060 | $579,352 | — |
| 2019 | 2019-12-31 | −$355,292 | −$143,798 | — |
| 2018 | 2018-12-31 | −$211,494 | −$1.4M | — |
| 2017 | 2017-12-31 | $1.2M | −$1.3M | −50.80% |
| 2016 | 2016-12-31 | $2.5M | $3.2M | — |
| 2015 · Dec 31 | 2015-12-31 | −$675,015 | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$57,000 | −$161,000 | — |
| 2014 | 2014-06-30 | $104,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly working capital
As of Jun 30, 2011
As of Sep 30, 2011
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$362,743 | $5.8M | — |
| Q4 2026 | 2026-03-31 | $511,107 | $5.5M | — |
| Q3 2026 | 2025-12-31 | −$4.5M | −$5.5M | — |
| Q2 2026 | 2025-09-30 | −$6.8M | −$7.5M | — |
| Q1 2026 | 2025-06-30 | −$6.1M | −$6.8M | — |
| Q4 2025 | 2025-03-31 | −$5.0M | −$7.0M | — |
| Q4 2024 | 2024-12-31 | $940,108 | −$2.6M | −73.48% |
| Q3 2024 | 2024-09-30 | $633,389 | −$3.5M | −84.54% |
| Q2 2024 | 2024-06-30 | $694,329 | −$4.7M | −87.17% |
| Q1 2024 | 2024-03-31 | $2.0M | −$4.4M | −68.47% |
| Q4 2023 | 2023-12-31 | $3.5M | −$3.4M | −48.74% |
| Q3 2023 | 2023-09-30 | $4.1M | −$3.6M | −46.80% |
| Q2 2023 | 2023-06-30 | $5.4M | −$3.1M | −36.71% |
| Q1 2023 | 2023-03-31 | $6.4M | −$2.6M | −28.86% |
| Q4 2022 | 2022-12-31 | $6.9M | −$3.3M | −32.60% |
| Q3 2022 | 2022-09-30 | $7.7M | −$3.2M | −29.56% |
| Q2 2022 | 2022-06-30 | $8.6M | −$2.9M | −25.38% |
| Q1 2022 | 2022-03-31 | $9.0M | $9.5M | — |
| Q4 2021 | 2021-12-31 | $10.3M | $10.0M | +4479.30% |
| Q3 2021 | 2021-09-30 | $10.9M | $10.6M | +3672.12% |
| Q2 2021 | 2021-06-30 | $11.5M | $11.1M | +2854.30% |
| Q1 2021 | 2021-03-31 | −$454,826 | −$416,235 | — |
| Q4 2020 | 2020-12-31 | $224,060 | $579,352 | — |
| Q3 2020 | 2020-09-30 | $289,829 | $653,939 | — |
| Q2 2020 | 2020-06-30 | $387,894 | $767,832 | — |
| Q1 2020 | 2020-03-31 | −$38,591 | $323,769 | — |
| Q4 2019 | 2019-12-31 | −$355,292 | −$143,798 | — |
| Q3 2019 | 2019-09-30 | −$364,110 | −$686,411 | — |
| Q2 2019 | 2019-06-30 | −$379,938 | −$939,013 | — |
| Q1 2019 | 2019-03-31 | −$362,360 | −$1.3M | — |
| Q4 2018 | 2018-12-31 | −$211,494 | −$1.4M | — |
| Q3 2018 | 2018-09-30 | $322,301 | −$1.4M | −80.83% |
| Q2 2018 | 2018-06-30 | $559,075 | −$1.3M | −70.19% |
| Q1 2018 | 2018-03-31 | $963,990 | −$1.2M | −55.71% |
| Q4 2017 | 2017-12-31 | $1.2M | −$1.3M | −50.80% |
| Q3 2017 | 2017-09-30 | $1.7M | −$1.3M | −42.75% |
| Q2 2017 | 2017-06-30 | $1.9M | −$1.3M | −41.11% |
| Q1 2017 | 2017-03-31 | $2.2M | −$838,379 | −27.81% |
| Q4 2016 | 2016-12-31 | $2.5M | $3.2M | — |
| Q3 2016 | 2016-09-30 | $2.9M | $3.6M | — |
| Q2 2016 | 2016-06-30 | $3.2M | $3.2M | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $3.0M | $3.5M | — |
| Q4 2015 · Dec 31 | 2015-12-31 | −$675,015 | −$346,015 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$708,000 | −$518,000 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | −$57,000 | −$161,000 | — |
| Q3 2015 | 2015-03-31 | −$456,000 | — | — |
| Q2 2015 | 2014-12-31 | −$329,000 | — | — |
| Q1 2015 | 2014-09-30 | −$190,000 | — | — |
| Q4 2014 | 2014-06-30 | $104,000 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | −$9.8M | — | — |
| As of Jun 30, 2011 | 2011-06-30 | −$6.7M | — | — |
Protagenic Therapeutics, Inc.\new working capital trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's working capital increased from $104,000 to $511,107, a change of $407,107. The latest reported quarter, Q1 2027, shows −$362,743.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗